-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

631.P1.53 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Symposia: Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)

Haotian Zhang1 and Huichun Zhan, MD2,3

1Graduate Program in Molecular & Cellular Biology, Stony Brook University, Stony Brook, NY
2Department of Medicine, Stony Brook School of Medicine, Stony Brook
3Northport VA Medical Center, Northport

Tamara Codilupi1*, Jakub Szybinski, PhD1*, Sime Brkic, PhD1*, Simona Stivala, PhD1*, Julie Yang, PhD2*, Nilabh Ghosh, PhD1*, Katarzyna Buczak, PhD3*, Jakob Passweg, MD4*, Anne Angelillo-Scherrer, MD-PhD5, Stefan Dirnhofer, MD6*, Ross L. Levine, MD7, Richard Koche, PhD2,8* and Sara C. Meyer, MD, PhD1,9

1Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
2Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY
3Proteomics Core Facility Biozentrum, University of Basel, Basel, Switzerland
4Division of Hematology, University Hospital Basel, Basel, Switzerland
5Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital and University of Bern, Bern, Switzerland
6Department of Pathology, University Hospital Basel, Basel, Switzerland
7Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
8Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Center for Epigenetics, Memorial Sloan Kettering Cancer Center, New York, NY
9Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Saravanan Ganesan1*, Sarah Awan-Toor1*, Fabien Guidez, PhD2,3*, Nabih Maslah, PharmD, PhD4,5,6*, Celine Aoun1*, Panhong Gou, PhD1*, Chloe Guiguen1*, Juliette Soret, MD7*, Odonchimeg Ravdan8*, Valeria Bisio, PhD9*, Nicolas Dulphy, PhD10,11*, Marie-Hélène Schlageter, PharmD, PhD12*, Michele Souyri, PhD13*, Stephane Giraudier, MD, PhD1,4,14*, Jean-Jacques Kiladjian, MD1,15, Christine Chomienne, MD, PhD16* and Bruno Cassinat, PharmD, PhD1,6

1IRSL, Inserm UMRS 1131, Paris, France
2U1232/LNC Inserm, team Epi2THM, UBFC, Dijon, France
3Inserm UMRS 1131, Paris, FRA
4Universite de Paris Cite, Paris, France
5IRSL, INSERM UMR 1131, Paris, France
6AP-HP, Hopital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France
7Centre d'Investigations Cliniques, APHP, Hopital Saint-Louis, Paris, France
8Service de Biologie Cellulaire, Paris, France
9IRSL, Inserm U1160, Paris, FRA
10AP-HP, Hopital Saint-Louis, Laboratoire d'Immunologie et d'Histocompatibilite, Paris, France
11Université Paris-Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France
12Service de Biologie Cellulaire, Hôpital Saint-Louis AP-HP, PARIS, France
13Institut de Recherche St Louis, Université de Paris Cite, INSERM U1131, Paris, France
14AP-HP, Hopital Saint-Louis, Service de Biologie Cellulaire, Paris, France
15Centre d'Investigations Cliniques (INSERM CIC 1427), AP-HP, Hôpital Saint-Louis, Université Paris Cité, Paris, France
16Inserm UMR-S1131, Université De Paris, IRSL, HôPital Saint-Louis, Paris, FRA

Bao T. Le*, Yue Yang, PhD and Golam Mohi, PhD

Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA

Bella Banjanin1,2*, James Nagai3*, Yevin Mun4*, Inge Snoeren1,2*, Stijn Fuchs1,2*, Marek Weiler5*, Fabian Kiessling5*, Twan Lammers5*, Kishor Sivaraj6*, Ralf Adams6*, Cesar Nombela-Arrieta, PhD7*, Ivan Costa, PhD3* and Rebekka K. Schneider, MD, PhD1,2,8

1Department of Developmental Biology, Erasmus MC, Rotterdam, Netherlands
2Oncode Institute, Erasmus MC, Rotterdam, Netherlands
3Institute for Computational Genomics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
4Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
5Department of Experimental Molecular Imaging, RWTH Aachen University, Aachen, Germany
6Max Planck Institute for Molecular Biomedicine, Munster, Germany
7Laboratory of Experimental Hematology, Clinics for Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
8Institute for Cell and Tumor Biology, RWTH Aachen University Hospital, Lemiers, Netherlands

Veronika Kropackova1*, Jan Gursky, PhD2*, Jana Balounova, PhD3*, Vladimir Korinek, PhD1*, Vladimir Divoky, PhD2 and Lucie Lanikova, PhD1

1Department of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
2Department of Biology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
3Czech Centre for Phenogenomics & Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic

Tanner H Robison, MS1*, Manisha Solipuram2*, Winston Y Lee, MD, PhD3*, Kathryn Luker2*, Kristen M. Pettit4, Moshe Talpaz, MD5, Dariya Malyarenko2*, Thomas Chenevert2*, Brian Ross2* and Gary Luker2*

1Biomedical Engineering, University of Michigan, Ann Arbor, MI
2University of Michigan, Ann Arbor, MI
3Department of Pathology, University of Michigan, Ann Arbor, MI
4Rogel Cancer Center, The University of Michigan, Ann Arbor, MI
5University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Laura Massarenti1*, Trine A. Knudsen, MD2*, Christian Enevold, PhD1*, Vibe Skov, PhD2*, Lasse Kjær, PhD2*, Morten Kranker Larsen, MSc2,3*, Claus Henrik Nielsen, MD1* and Hans Carl Hasselbalch, MD2

1Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
2Department of Hematology, Zealand University Hospital, Roskilde, Denmark
3Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Ryan Yen, BSc1,2, Lambert Yue, PhD1*, Steven Pelech, PhD1,3* and Xiaoyan Jiang, MD, PhD1

1Department of Medicine, University of British Columbia, Vancouver, BC, Canada
2Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada
3Kinexus Bioinformatics Corporation, Vancouver, BC, Canada

Danny V Jeyaraju, PhD1*, Sheida Hayati2*, Ann Polonskaia1*, Maryam Alapa1*, Manuel Ugidos, PhD3*, Andrew Browne4*, Alberto Risueño, PhD5*, Patrick Hagner, PhD6*, Vikas Gupta, MD, FRCP, FRCPath7, Moshe Talpaz, MD8, Christopher Hernandez, MSc9*, Vincent Chia, PhD9*, Patricia Martin-Regueira, MD9,10*, Daniel Lopes de Menezes, PhD9*, Ross La Motte-Mohs11*, Rajasekhar NVS Suragani4* and Anita K. Gandhi, PhD6

1Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ
2Bristol Myers Squibb, Princeton
3BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol-Myers Squibb Company, Seville, Spain
4Bristol Myers Squibb, Cambridge, MA
5Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain
6Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ
7Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada
8University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
9Bristol Myers Squibb, Princeton, NJ
10Bristol Myers Squibb, Madrid, Spain
11Translational Development & Diagnostics, Bristol Myers Squibb, Summit, NJ

Srdan Verstovsek, MD, PhD1, John Mascarenhas, MD2, Raajit K Rampal, MD, PhD3, Daniela Cilloni, MD4*, Claire N. Harrison, DM5, Brian Jacoby, MD, MBA6*, Robert J. Slack, PhD, FRSB7*, Vassilios Aslanis, MSc, PhD8*, Bobby Singh, MBBS, APGDPM9* and Bertil Lindmark, MD, PhD8*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
4University Hospital San Luigi Gonzaga, Orbassano, Italy
5Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
6Galecto Inc, Copenhagen, Denmark
7Galecto, Inc., London, United Kingdom
8Galecto, Copenhagen, Denmark
9Galecto, Kuala Lumpur, Malaysia

Yücel Erbilgin1*, Christophe Desterke, PhD2*, Annelise Bennaceur Griscelli, MD, PhD3* and Ali G Turhan, MD, PhD4

1Inserm U1310, Villejuif, France
2Inserm U1310, University Paris Saclay, Villejuif, FRA
3Inserm UMS 45, CITHERA Center for iPSC Therapies, Evry, France
4INSERM U1310, Villejuif, France

C. Matthias Wilk, MD1*, Jessica LeBerichel, B.S.1*, Flurin Cathomas, MD2*, George Heaton, PhD3*, Orsolya Török, MD, PhD4*, Aymeric Silvin, PhD5*, Zhenyu Yue, PhD3*, Scott Russo, PhD2*, Florent Ginhoux, PhD5,6*, Jennifer Picarsic, MD7*, Carl E. Allen, MD, PhD8 and Miriam Merad, MD, PhD1,9*

1Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Precision Immunology Institute, New York, NY
2Icahn School of Medicine at Mount Sinai, Nash Family Department of Neuroscience, Brain & Body Research Center, Friedman Brain Institute, New York, NY
3Icahn School of Medicine at Mount Sinai, Friedman Brain Institute, New York, NY
4University of Pécs, Medical School, Department of Neurology, Pécs,, Hungary
5Inserm U1015, Gustave Roussy Cancer Campus, Villejuif, France
6Singapore Immunology Network, Singapore, SGP
7University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh O, Pittsburgh, PA
8Division of Pediatric Hematology and Oncology, Baylor College of Medicine, Houston, TX
9Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Shaowei Qiu, MD1,2*, Vipul Sheth1*, Chengcheng Yan, MD1*, Juan Liu3*, Balu K. Chacko4*, Hui Li, BS1*, David Crossman5*, Seth D. Fortmann6,7*, Sajesan Aryal, BS1, Maria B. Grant6*, Robert S. Welner, PhD1*, Andrew J. Paterson, PhD1*, Adam R. Wende4*, Victor M Darley-Usmar, PhD4*, Rui Lu, PhD8, Jason W. Locasale3* and Ravi Bhatia, MD9

1Division of Hematology/Oncology, University of Alabama At Birmingham, Birmingham, AL
2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC
4Department of Pathology, Mitochondrial Medicine Laboratory, University of Alabama at Birmingham, Birmingham, AL
5Genomics Core Facility, University of Alabama at Birmingham, Birmingham, AL
6Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, AL
7Medical Scientist Training Program (MSTP), School of Medicine, University of Alabama at Birmingham, Birmingham, AL
8Division of Hematology and Oncology, Department of Medicine, University of Alabama At Birmingham, Birmingham, AL
9Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

Melissa Lock1*, Damien Luque Paz1*, Nils Hansen1*, Tiago Almeida Fonseca1*, MARC Usart2*, Shivam Rai1*, Hui Hao-Shen1*, Gabriele Mild1*, Stephan Dirnhofer3*, Radek C. Skoda1 and Jan Stetka1*

1Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
2Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, BASEL, Switzerland
3Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland

Nicolas Papadopoulos1,2,3*, Ajda Pristavec1*, Gabriel Levy, MD1,2,3*, Audrey Nédélec, PhD1,2,3*, Judith Staerk, PhD4* and Stefan N. Constantinescu, MD, PhD1,2,3,5

1de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
2WELBIO (Wallon Excellence in Life Sciences and Biotechnology), Brussels, Belgium
3Ludwig Institute for Cancer Research, Brussels, Belgium
4University of Oslo, Oslo, NOR
5Oxford University, Nuffield Department of Medicine, Ludwig Institute for Cancer Research, Oxford, United Kingdom

*signifies non-member of ASH